Ph3 Efficacy & Safety of GIVinostat vs Hydroxyurea in JAK2V617F + high risk Polycythemia vera
Phase III Clinical Trial
Randomized open-label multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL (DSC/08/2357/32)
Participating Locations